Current status of tuberculosis and recombinant bacillus Calmette-Guérin vaccines  by Ohara, Naoya
Journal of Oral Biosciences 54 (2012) 92–95Contents lists available at SciVerse ScienceDirectJournal of Oral Biosciences1349-00
http://d
n Tel.:
E-mjournal homepage: www.elsevier.com/locate/jobReviewCurrent status of tuberculosis and recombinant bacillus
Calmette-Gue´rin vaccinesNaoya Ohara n
Oral Microbiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8525, Japana r t i c l e i n f o
Article history:
Received 11 July 2011
Received in revised form
8 August 2011
Accepted 12 August 2011





Vaccine79/$ - see front matter & 2012 Japanese Asso
x.doi.org/10.1016/j.job.2012.04.002
þ81 86 235 6655; fax: þ81 86 235 6659.
ail address: oharan@md.okayama-u.ac.jpa b s t r a c t
Tuberculosis (TB) is an infectious disease and a global concern of enormous proportions. One-third of
the world’s population is latently infected with Mycobacterium tuberculosis, and 2 million people die
from TB annually. The only currently available vaccine—bacillus Calmette-Guerin (BCG)—is the most
extensively used vaccine ever, with a record 3 billion doses administered during the last 4 decades.
Because BCG is a live attenuated vaccine, it can be developed by genetic engineering to serve as a
foreign antigen–producing multivalent vaccine. A new antibiotic-free host–vector system has been
developed that expresses the foreign antigen from BCG by using a thymidylate synthase ThyX-deletion
mutant of BCG and a plasmid harboring the thyX gene. This host–vector system is stable and can be
useful for clinical purposes.
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I started my study on the pathogenicity of mycobacterial species,
including the causative agent of tuberculosis (TB), Mycobacterium
tuberculosis (MTB), and bacillus Calmette-Guerin (BCG) vaccine in
1990. Several Mycobacterium species, especially pathogenic species,
are slow-growing. MTB and BCG have a doubling time of at least
15 h, and it takes 3–6 weeks for their colonies to be visible on solid
media. These species tend to aggregate. Even when bacteria is
grown in liquid medium containing detergents, considerable clump-
ing occurs. These properties have greatly hindered the understand-
ing of the genetic makeup of mycobacteria. Genetic manipulation ofciation for Oral Biology. Publishedmycobacterial species and the possibilities of the use of the BCG
vaccine fascinated me.2. Tuberculosis and the tubercle bacillus
Mycobacterial species, especially MTB, are very attractive
microorganisms. TB is one of the oldest human plagues [1]. Signs
of skeletal TB were evident in Europe in Neolithic times (8000 BC),
in ancient Egypt (1000 BC), and in the pre-Columbian NewWorld.
TB is thought to be one of the microorganisms that have adapted
most successfully to human beings and is the most common
cause of infectious disease–related mortality worldwide. Despite
its long history, MTB continues to cause more deaths than any
other bacterial pathogen and is yet to be completely controlled.by Elsevier B.V. All rights reserved.
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public health concern worldwide. It is estimated that one-third of
the world’s population is latently infected with MTB, and approxi-
mately 9.4 million new cases of TB are reported annually, with
1.7 million people dying of the disease each year [2]. MTB usually
enters the host on inhalation of an infected aerosol; the bacilli are
then phagocytosed by alveolar macrophages. Intracellular repli-
cation of the bacterium results in a primary lesion, which is
followed by lymphohematogenous dissemination and the forma-
tion of secondary lesions in the lungs and other organs [3].
Uncontrolled MTB growth at the site of infection is associated
with extensive lung damage, ultimately leading to the death of
the host. However, in most individuals, disease progression is
arrested at this stage by an acquired immune response, resulting
in the formation of granulomatous lesions, and a clinically latent
state ensues. Post-primary disease state results from the subse-
quent reactivation of dormant bacilli [3,4].3. BCG
The only currently available vaccine against TB—Mycobacterium
bovis BCG—is the live attenuated strain of M. bovis obtained by
Albert Calmette and Camille Gue´rin at the Institute Pasteur in Lille,
France. They subcultured a virulent strain ofM. bovis isolated from a
cow with tuberculosis every 3 weeks on potato slices cooked in beef
bile supplemented with glycerol. In 1921, after 230 passages over
the course of 13 years, they found the culture was attenuated
without reverting to the virulent phenotype but retained limited
invasiveness in experimental animals [5].
BCG is thought to be effective against disseminated forms of
TB in children, such as military TB and tuberculous meningitis,
although most of the supporting data were derived from observa-
tional and case-control studies [6]. BCG vaccination was also
shown to protect against leprosy in a controlled trial [7]. How-
ever, the protective efﬁcacy conferred by BCG vaccination against
pulmonary TB in adults has been variable in clinical trials (in the
range of 0–80%), depending on the population, country, and BCG
sub-strain used [8,9]. Therefore, a more effective vaccination
strategy against TB is urgently needed.4. Recombinant BCG vaccines
Although the protective efﬁcacy of BCG is variable in humans,
it remains the sole available vaccine for TB. BCG has many
properties of an ideal vaccine: it has excellent adjuvant activity,
it can be given at birth or any time thereafter, and a single
inoculum can produce long-lasting immunity for several days to
10 years. It also has a long-standing safety proﬁle. Since 1921,
more than 3 billion doses of BCG have been administrated
worldwide, with a remarkably low incidence of adverse effects
in immunocompetent individuals. BCG is stable and inexpensive
to produce. It has also been licensed for use in bladder cancer
treatment. Because of these attributes, many investigators have
focused their efforts on developing BCG into a novel vaccine
vehicle that is capable of simultaneously expressing recombinant
antigens of multiple pathogens [10].
In the mid-1980s, many advances in the ﬁeld helped provide
an understanding of the development of the mycobacterial
genetic makeup and the molecular biology of mycobacteria. Jacob
et al. ﬁrst reported the development of the Escherichia
coli–Mycobacterium shuttle phasmid [11]. In 1990, Yamada’s
group established a foreign antigen secretion system in myco-
bacteria in which the alpha antigen secreted by Mycobacterium
kansasii was used as a carrier [12]. In this system, a B-cell epitopeof human immunodeﬁciency virus type-1 (HIV-1) p17gag was
secreted by BCG along with the alpha antigen. This was the ﬁrst
report on the expression and secretion of a foreign virus antigen
from BCG. Two later reports ﬁrst demonstrated the augmentation
of immune responses by recombinant BCG (rBCG) [13,14]. At that
time, the editor of Nature (London) evaluated these rBCGs as
‘‘rebirth of a star performer’’ [15]. Within 2 decades, many rBCGs
were constructed, and animal experiments were performed using
these rBCGs.
Many foreign antigens, including viral antigens, bacterial anti-
gens, parasitic antigens, allergens, and cytokines have been used to
express BCG [10,16]. I focused on rBCG for mycobacterial diseases.5. rBCG producing large amounts of protective antigens
Several different types of TB vaccines have been developed
using different technological platforms, including subunit
vaccines, mycobacterial proteins and peptides in adjuvants, atte-
nuated vectors expressing mycobacterial antigens, attenuated
mutants of MTB, DNA vaccines, rBCG strains, and live attenuated
vaccines. BCGs are among the most potent candidates.
Several strategies have been developed to produce effective
rBCGs against mycobacterial diseases. One approach to increase
the efﬁcacy of BCG is to construct rBCG that overproduces
autologous protective antigens. Baumgart et al. ﬁrst constructed
rBCG expressing the 18-kDa protein of Mycobacterium leprae. It
stimulated the production of an antibody against the 18-kDa
protein and lymphocyte proliferative responses in mice [17].
We have shown that immunization of mice with rBCG over-
producing and secreting Ag85A rBCG/85A reduced M. leprae
multiplication in the footpads of mice [18]. Immunization with
rBCG/BA51, which results in the overproduction and secretion of
3 components of the Ag85 complex, i.e., Ag85A, Ag85B (also called
alpha antigen), and MPB51, was more effective than that with
rBCG/85A in inhibiting M. leprae multiplication in the footpads of
mice [19]. Immunization with these rBCGs, especially rBCG/BA51,
also induced greater protection against MTB challenge by aerosol,
both in mice and guinea pigs relative to parent BCG (published
elsewhere).
rBCG that overproduced and secreted the Ag85 protein was
also constructed and reported by other investigators. Horwitz
et al., reported that use of rBCG that expressed and secreted the
Ag85B protein (rBCG30) improved protection in a guinea pig
model of TB [20]. Sugawara et al. reported that rBCG with an
Ag85A gene insert (rBCG-Ag85A[Tokyo]) had better protective
efﬁcacy against M. tuberculosis infection than did that with Ag85A
DNA [21]. The higher protective efﬁcacy induced by rBCG-
Ag85A[Tokyo] was also shown in cynomolgus monkeys [22].
The antigens that were present in MTB but not in BCG were also
present in rBCG. The RD1 locus of MTB contains genes for the
protective ESAT-6 and CFP-10 antigens and is not present in BCG.
Compared to BCG, rBCG that expressed the RD1 locus was reported
to induce increased protection in mice and guinea pigs [23]. How-
ever, this strain has also been reported to have increased virulence.6. rBCG-expressing immunomodulating molecules
BCG can also produce molecules that enhance host immune
systems. Hess et al. constructed rBCG that secretes listeriolysin (Hly)
of Listeria monocytogenes [24]. Hly is a pore-forming sulfhydryl-
activated cytolysin that alters the membrane permeability of
phagosomes in host cells. The rBCG expressing Hly improved
major histocompatibility complex (MHC) class I presentation of
co-phagocytosed soluble proteins. They also showed that a urease
N. Ohara / Journal of Oral Biosciences 54 (2012) 92–9594C-deﬁcient hlyþ rBCG (DureC hlyþ rBCG) vaccine providing an
intraphagosomal pH closer to the acidic pH optimum for Hly
activity exhibited higher vaccine efﬁcacy than did the parental
BCG in mice [25].
rBCG vaccines expressing cytokines, including interleukin (IL)-2,
IL-4, IL-6, IL-15, IL-18, granulocyte-macrophage colony-stimulating
factor (GM-CSF), interferon-g, and monocyte chemotactic protein 3,
were also constructed and their protective activities against MTB
infection were evaluated [26–29]. IL-15 plays an important function
in the maintenance of memory CD8þ T cells. Mice immunized with
rBCG expressing IL-15 fused with the dominant antigen Ag85B
(rBCG-Ag85B-IL15) exhibited CD8þ and CD4þ T cell responses that
were stronger than those in mice immunized with rBCG-Ag85B.
Further, it provided robust protection in the lungs against intra-
tracheal MTB challenge [29].7. Construction of a new Host–vector system for rBCG
A large number of E. coli–Mycobacterium shuttle vectors have
been developed to introduce foreign genes into BCG. These genes
are maintained in the mycobacteria episomally or are integrated
into the genome. Most plasmid vectors contain antibiotic resis-
tance genes as selectable markers. These vectors would not be
suitable in the clinical application of recombinant vaccines
because there is a possibility of spreading of those genes to the
microbial ﬂora. Moreover, these gene product markers cannot
work as selectable markers for the vaccine in vivo.
Thymidine synthase has been recognized as an essential enzyme
in all free-living organisms. Organisms possess the canonical thy-
midylate synthase ThyA (EC 2.1.1.45), which is commonly found in
eukaryotes and many eubacteria, and/or a novel FAD-dependent
thymidylate synthase, ThyX (EC 2.1.1.148) [30]. ThyX also catalyzes
the oxidation of NADPH. Only a few members of the suborder
Corynebacterineae possess both ThyA and ThyX.
We constructed a ThyX gene (thyX)-deletion mutant (DthyX)




















Fig. 1. Scheme of the new host–vector system in bacillus Calmette-Guerin (BCG)
based on the combination of the thyX-null mutant DthyX and the plasmid
harboring thyX. thyX* indicates deletion of thyX from the BCG genome. OriEco,
replication origin for Escherichia coli; OriM, replication origin for Mycobacterium.found that DthyX could grow on 7H10-ADC (albumin-dextrose-
catalase) agar plates but not on 7H10-ADS (albumin-dextrose-
sodium chloride) agar plates that did not contain catalase. This
result suggested that thyX on the mycobacterial plasmid could
possibly be used as a selectable marker in DthyX mutants using
the speciﬁed medium. To evaluate the usefulness of complemen-
tation as a marker, the E. coli–Mycobacterium shuttle vector
containing thyX was constructed (Fig. 1). DthyX possessing the
plasmid harboring thyX could grow on 7H10-ADS plates. To test
the stability of this shuttle vector in DthyX, the green ﬂuorescent
protein (GFP) gene was inserted into it as the foreign antigen
gene. The transformants expressing GFP retained the plasmid for
over 6 months (more than 86% of bacterial cells expressed GFP);
this suggests that this host–vector system is highly stable without
the use of antibiotic resistance genes (published elsewhere).
Therefore, the combination of the thyX-null mutant DthyX and
the plasmid harboring thyX is a new host–vector system in BCG
that abolishes the need for an antibiotic resistance gene as a
vector component.8. Conclusions
The development of a novel vaccine for TB, an exciting but
time-consuming task, is important for the control of TB. Once a
vaccine candidate is constructed, the evaluation of its efﬁcacy in
humans requires several decades. However, vaccines have the
potential to save lives of many people at once and thus have great
impact. We hope that individuals worldwide can be saved
through the use of novel vaccines.Conﬂict of interest
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